Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) (MALS verified)
抗体来源(Source)
Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
克隆号(Clone)
8G9
种属(Species)
Mouse
亚型(Isotype)
Human IgG1 | Human Kappa
偶联(Conjugate)
Unconjugated
抗体类型(Antibody Type)
Recombinant Monoclonal
种属反应性(Reactivity)
Virus
免疫原(Immunogen)
Recombinant HRSV (A) Glycoprotein G Protein is expressed from human 293 cells
特异性(Specificity)
Specific recognition of HRSV (A) Glycoprotein G Protein.
应用(Application)
Application | Recommended Usage |
ELISA | 0.1-125 ng/mL |
纯度(Purity)
95% as determined by SDS-PAGE.
90% as determined by SEC-MALS.
纯化(Purification)
Protein A purified / Protein G purified
制剂(Formulation)
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
重构方法(Reconstitution)
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
交叉验证(Cross Verification)
This product No cross-reactivity in ELISA with
HRSV (B) Glycoprotein G Protein, His Tag (Cat. No. GLG-V5144).

背景介绍
RSV病毒粒子表面的两种主要糖蛋白——附着糖蛋白(G)和融合糖蛋白(F)——控制着感染的初始阶段。G蛋白的中心区域包含一个由13个氨基酸组成的高度保守结构域,该结构域部分与一个半胱氨酸环结构域重叠,其中四个半胱氨酸以1-4和2-3方式连接,随后是一个高碱性的肝素结合域(HBD)。HBD可能是大多数细胞表面的硫酸乙酰肝素(HS)的附着位点。源自G蛋白HBD(第184–198位氨基酸)的一种肽段能够高效结合HEp-2细胞,并抑制RSV感染。
关键字: RSV-G抗体;RSV-G;Anti-RSV-G;百普赛斯;ACRO;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。